17,261 trials
Dysphagia · Non-Small Cell Lung Cancer · Lung Cancer
Primary: Number of Participants With Grade 2 or Higher Dysphagia — 32; 30; 13; 18 participants — p=0.3550
Hearing Loss · Stress
Primary: Communication Profile for Hearing Impaired: Maladaptive Strategies Subscale — 0.33; 0.37 score on a scale — p=0.69
Renal Failure
Primary: Measure Neutrophils to Measure Kidney Injury — 5.453; 5.630; 4.508; 4.546 log2 expression
Pathological Gambling
Primary: Clinical Global Impression Scale (CGI) — 2.88 units on a scale
Alcohol Drinking
Primary: Number of Drinks Consumed on Day 7 — 5.84; 5.61; 6.21 standard drinks
Kleptomania
Primary: Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (KM-YBOCS) — 5.4 units on a scale
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Pain · Peripheral Neuropathy
Primary: Percentage of Patients Who Have at Least a 50% Reduction (i.e., Success) in at Least 1 of the First 12 Chemotherapy Induced Peripheral Neuropathy (CIPN) Measurement…
GCT · Giant Cell Tumor of Bone
Primary: Percentage of Participants With Giant Cell Tumor Response — 85.7 percentage of participants
Head and Neck Cancer
Primary: Overall Objective Response — 4; 18; 2; 1 participants
Healthy
Primary: Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg) — 110.97 Ratio
Hypercholesterolemia
Primary: Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments — -46.2; -29.9; -19.6 Percent Change
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 15 of Each Treatment Period — -0.047; 0.081; 0.099; 0.048 Liters — p=<0.001
Multiple Myeloma
Primary: Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set) — 334 Participants — p=<0.0001